- Home
- ARL vs YMAB Comparison
ARL vs YMAB Comparison
Compare ARL & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- YMAB
- Stock Information
- Founded
- ARL 1999
- YMAB 2015
- Country
- ARL United States
- YMAB United States
- Employees
- ARL N/A
- YMAB N/A
- Industry
- ARL Building operators
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- YMAB Health Care
- Exchange
- ARL Nasdaq
- YMAB Nasdaq
- Market Cap
- ARL 187.2M
- YMAB 192.4M
- IPO Year
- ARL N/A
- YMAB 2018
- Fundamental
- Price
- ARL $13.35
- YMAB $4.10
- Analyst Decision
- ARL
- YMAB Buy
- Analyst Count
- ARL 0
- YMAB 11
- Target Price
- ARL N/A
- YMAB $18.09
- AVG Volume (30 Days)
- ARL 5.0K
- YMAB 220.0K
- Earning Date
- ARL 05-08-2025
- YMAB 05-13-2025
- Dividend Yield
- ARL N/A
- YMAB N/A
- EPS Growth
- ARL N/A
- YMAB N/A
- EPS
- ARL N/A
- YMAB N/A
- Revenue
- ARL $48,234,000.00
- YMAB $88,658,000.00
- Revenue This Year
- ARL N/A
- YMAB N/A
- Revenue Next Year
- ARL N/A
- YMAB $18.83
- P/E Ratio
- ARL N/A
- YMAB N/A
- Revenue Growth
- ARL N/A
- YMAB 4.92
- 52 Week Low
- ARL $9.43
- YMAB $3.84
- 52 Week High
- ARL $22.77
- YMAB $17.47
- Technical
- Relative Strength Index (RSI)
- ARL 60.02
- YMAB 47.50
- Support Level
- ARL $13.00
- YMAB $3.55
- Resistance Level
- ARL $13.82
- YMAB $5.04
- Average True Range (ATR)
- ARL 0.67
- YMAB 0.39
- MACD
- ARL 0.13
- YMAB 0.01
- Stochastic Oscillator
- ARL 81.18
- YMAB 36.91
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments; the acquisition, development, ownership and management of multifamily properties (Residential); and the acquisition, development, ownership, and management of commercial properties (Commercial), which predominantly comprise office properties. Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.